Evidence map›Paper›PMID 39040619›Full record

ArticleEuropean urology open science2024

Risk of Cancer-related Death for Men with Biopsy Grade Group 1 Prostate Cancer and High-risk Features: A European Multi-institutional Study.

Daimantas Milonas, Alexander Giesen, Tim Muilwijk, Charlotte Soenens, Gaëtan Devos, Zilvinas Venclovas, Alberto Briganti, Paolo Gontero, R Jeffrey Karnes, Piotr Chlosta and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Daimantas MilonasDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Alexander GiesenDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Tim MuilwijkDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Charlotte SoenensDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Gaëtan DevosDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Zilvinas VenclovasDepartment of Urology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Alberto BrigantiDepartment of Urology, University Vita Salute, San Raffaele Hospital, Milan, Italy.
Paolo GonteroDepartment of Urology, University of Turin, A.O.U. San Giovanni Battista-le Molinette, Turin, Italy.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Piotr ChlostaDepartment of Urology, Jagiellonian University Medical College, Krakow, Poland.
Frank ClaessensLaboratory of Molecular Endocrinology, KU Leuven, Leuven, Belgium.
Gert De MeerleerDepartment of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Wouter EveraertsDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Markus GraefenMartini Klinik am UKE GmbH, Hamburg, Germany.
Giansilvio MarchioroDepartment of Urology, University of Piemonte Orientale, Novara, Italy.
Rafael Sanchez-SalasDepartment of Surgery, Division of Urology, McGill University, Montreal, Canada.
Bertrand TombalDepartment of Urology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Henk Van Der PoelDepartment of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hendrik Van PoppelDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
Martin SpahnDepartment of Urology, Lindenhofspital Bern, Bern, Switzerland.
Steven JoniauDepartment of Urology, University Hospitals Leuven, Leuven, Belgium.
European Multicenter Prostate Cancer Clinical and Translational (EMPaCT) Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

International Society of Urological Pathology grade group 1 (GG 1) prostate cancer (PCa) is generally considered insignificant, with recent suggestions that it should even be considered as "noncancerous". We evaluated outcomes for patients with GG 1 PCa on biopsy (bGG 1) and high-risk features (prostate-specific antigen [PSA] >20 ng/ml and/or cT3-4 stage) to challenge the hypothesis that every case of bGG 1 PCa has a benign disease course. We used the multi-institutional EMPaCT database, which includes data for 9508 patients with high-risk PCa undergoing surgery. We included patients with bGG 1 PCa ( Patient summary: We assessed outcomes for patients diagnosed with low-grade prostate cancer on biopsy who also had one or two factors associated with high risk disease. Men with both of those risk factors had a higher risk of dying from their prostate cancer. Active treatment should be discussed for this subgroup of patients.

Indexed as

Gleason gradingHigh-risk prostate cancerOutcomesRadical prostatectomy

Identifiers

PMID39040619
PMCPMC11260856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.